References
- Fleming W.H., Alpern E.J., Uchida N., Ikuta K., Weissman I.L. Steel factor influences the distribution and activity of murine hematopoietic stem cells in vivo. Proc. Natl. Acad. Sci. USA 1993; 90: 3760–3764
- Oostendorp R.A.J., Reisbach G., Spitzer E., Thalmeier K., Deilnemann H., Mergenthaler H., Dormer P. VLA-4 and VCAM-1 are the principal adhesion molecules involved in the interaction between blast colony-forming cells and bone marrow stromal cells. Br. J. Haematol 1995; 91: 275–284
- Levesque J.P., Leavesley D.I., Nuitta S., Vadas M., Simmons P.J. Cytokines increase heman hematopoietic cell adhesiveness by activation of very late antigen (VLA)-4and VLA-5 integrins. J. Exp. Med 1995; 181: 1805–1815
- Ogawa M., Matsuzaki Y., Nishikawa S., Hayashi S-I., Kunisada T., Sudo T., Kina T., Nakauchi H., Nishikawa S-I. Expression and function of c-kit in hemopoietic progenitor cells. J. Exp. Med 1990; 174: 63–69
- Miyazawa K., Toyama K., Gotoh A., Hendrie P.C., Mantel C., Broxmeyer H.E. Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M017e cells. Blood 1994; 83: 137–145
- Jones P.H., Harper S., Watt F.M. Stem cell patterning and fate in the epidermis. Cell 1995; 80: 83–93
- Verfaille C.M., McGlave P.B. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. J. Clin. Invest 1992; 90: 1232–1241
- Gishizky M.L. Molecular mechanisms of Bcr-Abl induced oncogenesis. Cytokines and Molecular Therapy 1996; 2: 251–261
- Melo J.V. The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375–2384
- McWhirter J.R., Galasso D.L., Wang J.Y.J. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Molecular and Cellular Biology 1993; 13: 7587–7595
- Pendergast A.M., Quilliam L.A., Cripe L.D., Bassing C.H., Dai Z., Li N., Batzer A., Rabun K.M., Der C.J., Schlessinger J., Gishizky M.L. Bcr-Abl induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb-2 adaptor protein. Cell 1993; 75: 175–185
- Liu J.X., Wu Y., Zhen Ma G., Lu D., Haataja L., Heisterkamp N., Groffen J., Arlinghaus R.B. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Molecular and Cellular Biology 1996; 16: 998–1005
- Maru Y., Witte O.M. The Bcr gene encodes a novel serine/threonine kinase activity within a single exon. Cell 1991; 67: 459–468
- Boguski M.S., McCormick R. Proteins regulating Ras and its relatives. Nature 1993; 366: 643–654
- Pendergast A.M., Gishizky M.L., Havlik M.H., Witte O.N. SHI domain autophosphorylation of p210berabl is required for transformation but not growth factor independence. Molecular and Cellular Biology 1993; 13: 1728–1736
- Fainstcin E., Einat M., Gokkel E., Marcclle C., Croce CM., Gale R.P., Canaani G.E. Nucleotide sequence analysis of human Abl and Bcr-Abl cDNAs. Oncogene 1981; 4: 1477–1481
- Kharbanda S., Bharti A., Pei D., Wang J., Pandey P., Ren, Weichselbaum R., Walsh C.T., Kufe D. The stress response to ionizing radiation involves c-Abl dependent phosphorylation of SHPTP1. Proc. Natl. Acad. Sci. USA 1996; 93: 6898–6901
- Kufe D., et al. 1997, Unpublished observations
- Van Etten R.A., Jackson P., Baltimore D. The mouse type IV c-Abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989; 58: 669–678
- Goga A., McLaughlkn J., Pendergast A.M., Parmar K., Muller A., Rosenberg N., Witte O.M. Oncogenic activation of c-Abl within its last exon. Molecular and Cellular Biology 1993; 13: 4967–4975
- Kipreos E.T., Wang J.Y.J. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA. Science 1992; 256: 382–385
- Jackson P.K., Paskind M., Baltimore D. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. Oncogene 1993; 8: 1943–1956
- Welch P.J., Wang J.Y.J. Abrogation of retinoblastoma protein function by c-Abl through tyrosine kinase-dependent and -independent mechanisms. Molecular and Cellular Biology 1995; 15: 5542–5551
- Welch P.J., Wang J.Y.J. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 1993; 75: 779–790
- Shi Y., Alin K., Goff S.P. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-Abl transforming activity. Genes and Development 1995; 9: 2583–2597
- Dai Z., Pendergast A.M. Abi-2, a novel SH3-con-taining protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes and Development 1995; 9: 2569–2582
- Kipreos E.T., Wang J.Y.J. Differential phosphorylation of c-Abl in cell cycle determined by cdc 2 kinase and phosphatase activity. Science 1994; 248: 217–220
- Ren R., Ye Z.S., Baltimore D. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev 1994; 8: 783–795
- Duyster J., Baskaran R., Wang J.Y.J. Src homology 2 domain as a specificity determinant in the c-Abl mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc. Natl. Acad. Sci. USA 1995; 92: 1555–1559
- Cortez D., Kadlec L., Pendergast A.M. Structural and signaling requirements for Bcr-Abl mediated transformation and inhibition of apoptosis. Molecular and Cellular Biology 1995; 15: 5531–5541
- Gishizky J.L., Cortez D., Pendergast A.M. Mutant forms of growth factor binding protein-2 reverse Bcr-Abl induced transformation. Proc. Natl. Acad. Sci. USA 1995; 92: 10889–10893
- Raitano A.B., Hallpern J.R., Hambuch T.M., Sawyers C.L. The Bcr-AbI leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA 1995; 92: 11746–11750
- Muller A.J., Pendergast A.M., Parmar K., Mavlik M.H., Rosenberg M., Witte O.N. En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase. Proc. Natl. Acad. Sci. USA 1993; 90: 3457–3461
- Franz W.M., Berger P., Wang J.Y.J. Deletion of an n-terminal regulatory domain of the c-Abl tyrosine kinase activates its oncogenic potential. EMBO J 1989; 8: 137–147
- Papadopoulos P., Ridge S.A., Boucher C.A., Stocking C., Wiedemann L.M. The novel activation of Abl by fusion to an ets-related gene, TEL. Cancer Res 1995; 55: 34–38
- Wen S.T., Jackson R.K., Van Etter R.A. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb suppressor gene products. EMBO J 1995; 15: 1583–1595
- Kharbanda S., Ren R., Pandeyk P., Shafman R.D., Feller S.M., Welchselbaum R.R., Kufe D.W. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 1995; 376: 785–788
- Yuan Z.M., Huang Y.Y., Whang Y., Sawyers C., Weichselbaum R., Kharbanda S., Kufe D. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 1996; 382: 272–274
- Kharbanda S., Pandey P., Jin S., Bharti A., Yuan Z.M., Weichselbaum R., Weaver D., Kufe D. Functional interaction of DNA-PK and c-Abl in response to DNA damage. Nature 1997, In press
- Sattler M., Salgia R., Okuda K., Uemura N., Durstin M.A., Pisick E., Xu X., Li J.J., Prasad K.V., Griffin J.D. The proto-oncogene product p120cbl and the adaptor proteins CFKL and c-CRK link c-Abl, p190bcrabl and p210bcrabl to the phosphatidylinositol-3′ kinase pathway. Oncogene 1996; 12: 839–846
- Feller S.M., Knudsen B., Hanafusa H. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 1994; 13: 2341–2351
- Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326–1331
- Hartley K.O., GeU D., Smith G.C.M., Zhang H., Divecha N., Connelly M.A., Admon A., Lees-Miller S.P., Anderson C.W. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-1 kinase and the Ataxia Telangiectasia Gene Product. Cell 1995; 82: 849–856
- Kufe D., et al. 1994, Unpublished observations
- Knudsen E.X., Wang J.Y.J. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. B. C. 1996; 271: 8313–8320
- Wilson-Rawls Jeanne, Xie S., Liu J., Laneuville P., Arlinghaus R.B. p210bcrabl interacts with the inter-leukin receptor betac subunit and constitutively induces its tyrosine phosphorylation. Cancer Research 1996; 56: 3426–3430
- Bazzoni G., Carlesso M., Griffin J., Hemier M.E. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. Journal of Clinical Investigation 1997; 98: 521–528
- Salgia R., Sattler M., Pisick E., Li J-L., Griffin J.D. p210bcrabl induces formation of complexes containing focal adhesion proteins and the protooncogene product p120ccbl. Experimental Hematology 1996; 24: 310–313
- Salgia R., Brunkhorst B., Pisick E., Li J-L., Lo S.H., Chen L.B., Griffin J.D. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210bcabl. Oncogene 1995; 11: 1149–1155
- Carlesso N., Frank D.A., Griffin J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med 1996; 183: 811–820
- Henderson Y.C., Guo X.Y.D., Greenberger J., Deisseroth A. Potential role of Bcr-AbI in the activation of JAK 1 kinase. Clinical Cancer Research 1993; 3: 145–150
- Yuan Z.M., Utsugisawa T., Huang Y.Y., Ishiko T., Nakada S., Kharbanda S., Weicheselbaum R., Kufe D. Inhibition of Phosphatidylinositol 3-kinase by c-abl in The Genotoxic Stress Response. J. Biol. chem 1997; 272, in press